Core Viewpoint - A recent case involving counterfeit cancer medication, specifically a fake version of Anlotinib, has been exposed, highlighting significant consumer fraud and the dangers of unregulated drug sales in China [1][6]. Group 1: Company Overview - Anlotinib is the first original patented targeted drug for third-line treatment of advanced non-small cell lung cancer in China, developed by Chia Tai Tianqing Pharmaceutical over more than a decade [3][4]. - Since its approval in May 2018, Anlotinib's sales exceeded 1.2 billion yuan in its first year and reached between 4 billion to 4.5 billion yuan by 2020, setting sales records for domestic innovative drugs [4]. Group 2: Counterfeit Drug Case Details - The counterfeit Anlotinib was sold at 1,500 yuan per box, with a total of over 380 boxes sold within 10 months, amounting to approximately 280,000 yuan in illicit revenue [1][4]. - The counterfeit drugs were found to contain no active Anlotinib ingredients, consisting instead of ineffective substances like flour and starch [6][4]. Group 3: Consumer Impact and Behavior - Victims of the counterfeit scheme were primarily late-stage lung cancer patients and their families, who mistakenly believed they were purchasing life-saving medication, leading to severe health consequences and missed treatment opportunities [1][6]. - The marketing strategy of counterfeiters exploited patients' trust in "imported drugs," misleading them into believing they were receiving a legitimate alternative to the original medication [6][7]. Group 4: Regulatory and Legal Challenges - The case illustrates the complexities of consumer protection in cross-border drug purchases, including difficulties in identifying sellers and proving causation in health-related claims [9]. - Legal risks associated with cross-border drug purchases include potential violations of drug management laws and customs regulations, complicating the ability of consumers to seek redress [9].